An Open-label, Dose Escalation, Phase I Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients
Phase of Trial: Phase I
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Afuresertib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 29 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 21 Dec 2018 Planned End Date changed from 28 Dec 2018 to 30 Jan 2020.
- 18 Jul 2018 Planned End Date changed from 30 Jun 2018 to 28 Dec 2018.